Regeneron Pharmaceuticals Inc. buy JPMorgan Chase & Co.
Summary
This prediction is currently active. The prediction currently has a performance of 10.30%. This prediction currently runs until 17.06.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | -0.509% | -0.509% |
iShares Core DAX® | 1.056% | 1.056% |
iShares Nasdaq 100 | -1.886% | -0.160% |
iShares Nikkei 225® | 2.553% | 4.359% |
iShares S&P 500 | -0.434% | 0.224% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by JPMorgan_Chase___Co_ for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
02.08.24
02.08.25
26.08.24